PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Cash & equivalents declining -42.34% while Biotechnology shows -10.34% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -7.49%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-41.98%
Current assets growth ≥ 1.5x the Biotechnology median of -6.60%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-100.00%
PP&E growth ≥ 1.5x the Biotechnology median of -1.83%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-100.00%
≥ 1.5x the Biotechnology median of -0.63%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
≥ 1.5x the Biotechnology median of -5.13%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-48.73%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-46.67%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-39.56%
Above 1.5x Biotechnology median of -0.33%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Above 1.5x Biotechnology median of -0.07%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Below half Biotechnology median of -2.50%. Jim Chanos suspects poor profitability or large dividend drains.
99.72%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-51.92%
≥ 1.5x Biotechnology median of -5.59%. Joel Greenblatt sees stronger equity growth vs. peers.
-42.01%
≥ 1.5x Biotechnology median of -5.13%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
42.23%
Above 1.5x Biotechnology median 9.42%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.